A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.
Esophageal,
Gastric/Gastroesophageal,
Gastrointestinal
Phase III
Adults
Chemotherapy - cytotoxic,
Mol. targeted/Immunotherapy/Biologics
5-FU (Fluorouracil),
5FU continuous infusion,
Capecitabine,
Cisplatin,
Leucovorin,
Oxaliplatin,
Tislelizumab
Gibson, Mike
International
Vanderbilt University
05-05-2026
Eligibility
18 Years and older
ALL
false
Inclusion Criteria:
Histologically confirmed, locally advanced unresectable or metastatic gastric/ gastroesophageal junction (GEJ) adenocarcinoma.
No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
At least 1 measurable or nonmeasurable lesion per RECIST v1.1 as determined by investigator assessment.
Must be able to provide tumor tissues for biomarker assessment.
Eastern Cooperative Oncology Group (ECOG) Performance Status score 1.
Adequate organ function.
Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and 120 days after the last dose of tislelizumab.
Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for 120 days after the last dose of tislelizumab.
Exclusion Criteria:
Squamous cell or undifferentiated or other histological type gastric cancer (GC)
Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for 4 weeks before randomization.
Diagnosis with gastric or GEJ adenocarcinoma with positive human epidermal growth factor receptor 2 (HER2).
Active autoimmune diseases or history of autoimmune diseases that may relapse.
Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (at least once a week) and/or diuretics within 7 days prior to randomization
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Histologically confirmed, locally advanced unresectable or metastatic gastric/ gastroesophageal junction (GEJ) adenocarcinoma.
No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
At least 1 measurable or nonmeasurable lesion per RECIST v1.1 as determined by investigator assessment.
Must be able to provide tumor tissues for biomarker assessment.
Eastern Cooperative Oncology Group (ECOG) Performance Status score 1.
Adequate organ function.
Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and 120 days after the last dose of tislelizumab.
Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for 120 days after the last dose of tislelizumab.
Exclusion Criteria:
Squamous cell or undifferentiated or other histological type gastric cancer (GC)
Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for 4 weeks before randomization.
Diagnosis with gastric or GEJ adenocarcinoma with positive human epidermal growth factor receptor 2 (HER2).
Active autoimmune diseases or history of autoimmune diseases that may relapse.
Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (at least once a week) and/or diuretics within 7 days prior to randomization
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
